论文部分内容阅读
目的:探索建立基于肿瘤原代培养物免疫荧光染色评价化疗物选择性和特异性的新方法。方法:利用手术切除的丛状神经纤维瘤(PNF)组织,混合培养原代肿瘤细胞和非肿瘤细胞并使用尼罗替尼(Nilotinib)和伊马替尼(Imatinib)进行处理,测定细胞增殖和毒性。利用特异性免疫荧光抗体染色处理后的细胞,通过Image J软件计数肿瘤细胞和非肿瘤细胞并计算两者比例变化,评价药物效能。结果:药物处理后,细胞增殖的降低和毒性的增加与药物浓度成正比。荧光细胞计数显示肿瘤细胞和非肿瘤细胞数量在药物处理后均减少,但药物效能具有个体差异性。结论:利用特异性免疫荧光染色计数同一组织混合培养的肿瘤细胞和非肿瘤细胞在药物处理后比例变化,可以评价化疗药物的选择性和特异性。
OBJECTIVE: To establish a new method to evaluate the selectivity and specificity of chemotherapeutic agents based on immunofluorescent staining of tumor primary cultures. Methods: Surgical excision of plexiform neurofibroma (PNF) was used to culture primary tumor cells and non-tumor cells and treated with Nilotinib and Imatinib to determine cell proliferation and toxicity. The cells stained with specific immunofluorescence antibody were used to count the tumor cells and non-tumor cells by Image J software, and the ratio of the two was calculated to evaluate the drug efficacy. Results: After drug treatment, the decrease of cell proliferation and the increase of toxicity were proportional to the drug concentration. Fluorescent cell counts showed that the number of tumor cells and non-tumor cells decreased after drug treatment, but the drug efficacy was individual differences. Conclusion: The specific immunofluorescent staining of tumor cells and non-tumor cells mixed culture in the same tissue after drug treatment, the proportion of change, you can evaluate the selectivity and specificity of chemotherapy drugs.